NEUPHORIA THERAPEUTICS INC (NEUP) Stock Price, Forecast & Analysis
NASDAQ:NEUP • US64136E1029
NEUP Key Statistics, Chart & Performance
The current stock price of NEUP is 4.35 USD. In the past month the price increased by 5.69%. In the past year, price decreased by -12.5%.
NEUP Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NEUP. When comparing the yearly performance of all stocks, NEUP is a bad performer in the overall market: 78.37% of all stocks are doing better.
NEUP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NEUP. The financial health of NEUP is average, but there are quite some concerns on its profitability.
NEUP Financial Highlights
Over the last trailing twelve months NEUP reported a non-GAAP Earnings per Share(EPS) of -3.76. The EPS decreased by -130% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.64% | ||
| ROE | -75.71% | ||
| Debt/Equity | 0 |
NEUP Forecast & Estimates
9 analysts have analysed NEUP and the average price target is 9.96 USD. This implies a price increase of 129.01% is expected in the next year compared to the current price of 4.35.
For the next year, analysts expect an EPS growth of -1551.32% and a revenue growth -100% for NEUP
NEUP Ownership
NEUP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.48 | 396.512B | ||
| AMGN | AMGEN INC | 16.63 | 202.199B | ||
| GILD | GILEAD SCIENCES INC | 16.97 | 187.492B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.39 | 119.063B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.78 | 82.713B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.19 | 44.834B | ||
| INSM | INSMED INC | N/A | 34.336B | ||
| NTRA | NATERA INC | N/A | 30.104B | ||
| BIIB | BIOGEN INC | 12.62 | 28.19B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.691B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NEUP
Company Profile
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is headquartered in Burlington, Massachusetts and currently employs 7 full-time employees. Its lead drug candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, as-needed treatment of social anxiety disorder and for the chronic treatment of post-traumatic stress disorder. BNC210 is a well-tolerated, broad-spectrum antianxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, the Company has two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.
Company Info
NEUPHORIA THERAPEUTICS INC
100 Summit Dr
Burlington MASSACHUSETTS US
Employees: 7
NEUPHORIA THERAPEUTICS INC / NEUP FAQ
What does NEUP do?
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is headquartered in Burlington, Massachusetts and currently employs 7 full-time employees. Its lead drug candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, as-needed treatment of social anxiety disorder and for the chronic treatment of post-traumatic stress disorder. BNC210 is a well-tolerated, broad-spectrum antianxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, the Company has two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.
What is the stock price of NEUPHORIA THERAPEUTICS INC today?
The current stock price of NEUP is 4.35 USD. The price increased by 1.87% in the last trading session.
What is the dividend status of NEUPHORIA THERAPEUTICS INC?
NEUP does not pay a dividend.
What is the ChartMill technical and fundamental rating of NEUP stock?
NEUP has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists NEUP stock?
NEUP stock is listed on the Nasdaq exchange.
What is the expected growth for NEUP stock?
The Revenue of NEUPHORIA THERAPEUTICS INC (NEUP) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the ownership details for NEUP stock?
You can find the ownership structure of NEUPHORIA THERAPEUTICS INC (NEUP) on the Ownership tab.